- Home
- IMMP vs TNGX Comparison
IMMP vs TNGX Comparison
Compare IMMP & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- TNGX
- Stock Information
- Founded
- IMMP 1987
- TNGX 2014
- Country
- IMMP Australia
- TNGX United States
- Employees
- IMMP N/A
- TNGX N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- IMMP Health Care
- TNGX Health Care
- Exchange
- IMMP Nasdaq
- TNGX Nasdaq
- Market Cap
- IMMP 211.1M
- TNGX 317.4M
- IPO Year
- IMMP N/A
- TNGX N/A
- Fundamental
- Price
- IMMP $1.86
- TNGX $1.10
- Analyst Decision
- IMMP Buy
- TNGX Strong Buy
- Analyst Count
- IMMP 2
- TNGX 7
- Target Price
- IMMP $8.50
- TNGX $12.33
- AVG Volume (30 Days)
- IMMP 648.0K
- TNGX 542.7K
- Earning Date
- IMMP 05-16-2025
- TNGX 05-12-2025
- Dividend Yield
- IMMP N/A
- TNGX N/A
- EPS Growth
- IMMP N/A
- TNGX N/A
- EPS
- IMMP N/A
- TNGX N/A
- Revenue
- IMMP $3,019,249.00
- TNGX $42,069,000.00
- Revenue This Year
- IMMP $11.25
- TNGX N/A
- Revenue Next Year
- IMMP $10.22
- TNGX N/A
- P/E Ratio
- IMMP N/A
- TNGX N/A
- Revenue Growth
- IMMP 24.11
- TNGX 15.17
- 52 Week Low
- IMMP $1.32
- TNGX $1.11
- 52 Week High
- IMMP $3.34
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- IMMP 53.43
- TNGX 33.44
- Support Level
- IMMP $1.44
- TNGX $1.38
- Resistance Level
- IMMP $2.71
- TNGX $1.56
- Average True Range (ATR)
- IMMP 0.17
- TNGX 0.16
- MACD
- IMMP 0.05
- TNGX -0.01
- Stochastic Oscillator
- IMMP 29.75
- TNGX 9.90
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.